Celcuity’s First-in-Class Drug Gets FDA Approval in Most Common Type of Breast Cancer - MedCity News
Celcuity has received FDA approval for its new breast cancer treatment, Revtorpyk, which targets HR-positive, HER2-negative breast cancer without PIK3CA mutations, using a dual approach to inhibit key cancer pathways. The drug is expected to launch in late Q3 2023, with a potential market opportunity exceeding $10 billion, and plans for further studies in other cancer types are underway.
The FDA approval of Celcuity's Revtorpyk, a first-in-class drug targeting both PI3K and mTOR pathways in HR-positive, HER2-negative breast cancer, presents a significant market opportunity, estimated at over $10 billion in the U.S. alone. For professionals in healthtech and biotech, this underscores the potential of dual-targeted therapies in oncology and highlights the importance of effective management of adverse effects like mucositis to ensure patient adherence and commercial success. As Revtorpyk moves towards broader applications in other cancers, monitoring its clinical trials and regulatory submissions could provide valuable insights for investment and partnership opportunities in precision medicine and oncology drug development.